Eating disorders are on the rise. GLP-1s could make things worse.

GLP-1 weight-loss drugs are one of the biggest biotech breakthroughs of the last decade. But to some clinical psychologists, they can represent something more sinister--a potential trigger for eating disorders. A new report suggests that the global incidence of anorexia nervosa and bulimia nervosa shot up between 1990 and 2023--by a whopping 71%. By 2023, there were an estimated 18.1 million people living with one of these two disorders.